Literature DB >> 15899310

NONMEMory: a run management tool for NONMEM.

Justin J Wilkins1.   

Abstract

NONMEM is an extremely powerful tool for nonlinear mixed-effect modelling and simulation of pharmacokinetic and pharmacodynamic data. However, it is a console-based application whose output does not lend itself to rapid interpretation or efficient management. NONMEMory has been created to be a comprehensive project manager for NONMEM, providing detailed summary, comparison and overview of the runs comprising a given project, including the display of output data, simple post-run processing, fast diagnostic plots and run output management, complementary to other available modelling aids. Analysis time ought not to be spent on trivial tasks, and NONMEMory's role is to eliminate these as far as possible by increasing the efficiency of the modelling process. NONMEMory is freely available from http://www.uct.ac.za/depts/pha/nonmemory.php.

Mesh:

Year:  2005        PMID: 15899310     DOI: 10.1016/j.cmpb.2005.02.003

Source DB:  PubMed          Journal:  Comput Methods Programs Biomed        ISSN: 0169-2607            Impact factor:   5.428


  24 in total

1.  Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients.

Authors:  Justin J Wilkins; Grant Langdon; Helen McIlleron; Goonaseelan Colin Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Eur J Clin Pharmacol       Date:  2006-05-10       Impact factor: 2.953

2.  Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption.

Authors:  Justin J Wilkins; Radojka M Savic; Mats O Karlsson; Grant Langdon; Helen McIlleron; Goonaseelan Pillai; Peter J Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191

3.  Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria.

Authors:  Joel Tarning; Rose McGready; Niklas Lindegardh; Elizabeth A Ashley; Mupawjay Pimanpanarak; Benjamas Kamanikom; Anna Annerberg; Nicholas P J Day; Kasia Stepniewska; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Antimicrob Agents Chemother       Date:  2009-06-29       Impact factor: 5.191

4.  Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients.

Authors:  Grant Langdon; Justin Wilkins; Lynn McFadyen; Helen McIlleron; Peter Smith; Ulrika S H Simonsson
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

5.  Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.

Authors:  Martin Johnson; Magdalena Kozielska; Venkatesh Pilla Reddy; An Vermeulen; Cheryl Li; Sarah Grimwood; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Pharm Res       Date:  2011-06-07       Impact factor: 4.200

6.  HIV/AIDS patients display lower relative bioavailability of efavirenz than healthy subjects.

Authors:  Jackson K Mukonzo; Sarah Nanzigu; Dinko Rekić; Paul Waako; Daniel Röshammar; Michael Ashton; Jasper Ogwal-Okeng; Lars L Gustafsson; Eleni Aklillu
Journal:  Clin Pharmacokinet       Date:  2011-08       Impact factor: 6.447

7.  Bilirubin-a potential marker of drug exposure in atazanavir-based antiretroviral therapy.

Authors:  Dinko Rekić; Oskar Clewe; Daniel Röshammar; Leo Flamholc; Anders Sönnerborg; Vidar Ormaasen; Magnus Gisslén; Angela Abelö; Michael Ashton
Journal:  AAPS J       Date:  2011-09-13       Impact factor: 4.009

8.  Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patients.

Authors:  Daniel Röshammar; Ulrika S H Simonsson; Håkan Ekvall; Leo Flamholc; Vidar Ormaasen; Jan Vesterbacka; Eva Wallmark; Michael Ashton; Magnus Gisslén
Journal:  J Pharmacokinet Pharmacodyn       Date:  2011-10-02       Impact factor: 2.745

9.  Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.

Authors:  Imke H Bartelink; Jaap J Boelens; Robbert G M Bredius; Antoine C G Egberts; Chenguang Wang; Marc B Bierings; Peter J Shaw; Christa E Nath; George Hempel; Juliette Zwaveling; Meindert Danhof; Catherijne A J Knibbe
Journal:  Clin Pharmacokinet       Date:  2012-05-01       Impact factor: 6.447

10.  Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.

Authors:  Joel Tarning; Palang Chotsiri; Vincent Jullien; Marcus J Rijken; Martin Bergstrand; Mireille Cammas; Rose McGready; Pratap Singhasivanon; Nicholas P J Day; Nicholas J White; Francois Nosten; Niklas Lindegardh
Journal:  Antimicrob Agents Chemother       Date:  2012-08-27       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.